– Phase 1 Results from the Phase 1/3 FIGHT Study Evaluating Bemarituzumab and mFOLFOX6 in Advanced Gastric and Gastric Esophageal Junction (GEJ) Cancer –
– Trial Design of a Randomized Phase 2 study of cabiralizumab + nivolumab ± chemotherapy in advanced pancreatic ductal adenocarcinoma –
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced two upcoming presentations at the 2019 Gastrointestinal Cancer Symposium being held in San Francisco, January 17-19, 2019. Data will be presented from the Phase 1/3 FIGHT Study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer. The study design of the randomized phase 2 study of cabiralixumab in combination with nivolumab and chemotherapy in advanced pancreatic ductal adenocarcinoma will also be presented. Here are the details of the two poster presentations:
| Title: | Phase 1 Results from the Phase 1/3 FIGHT Study Evaluating bemarituzumab and mFOLFOX6 in Advanced Gastric/GEJ Cancer |
| Abstract Number: | Board J1, Abstract #91 |
| Poster Session: | A – Cancer of the Esophagus and Stomach |
| Date & Time: | Thursday, January 17, 19, 11:30-1pm and 5:30-6:30pm |
| Title: | A Randomized Phase 2 Study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in Advanced Pancreatic Ductal Adenocarcinoma (PDAC) |
| Abstract Number: | Board Q4 Abstract #TPS465 |
| Poster Session: | B – Pancreatic, Small Bowel, Hepatobiliary |
| Date & Time: | Friday, January 18, 2019, 11:30-1pm and 5:30-6:30pm |
The poster abstracts will be available on January 14, 2019 at 5:00 PM EST at the ASCO Meeting Library and the posters can be found on Five Prime Therapeutics’ Scientific Publications page after presentation at the conference.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.